Bio-Rad Laboratories, Inc. (BIO) Stock Price: $297.17+5.86 (+2.01%)
The total return cagr for Bio-Rad Laboratories, Inc. (BIO) stock is 31.77% over the past 12 months. The 3 year average growth rate is -6.28% and the 5 year cagr is -12.56%. Total return includes dividends reinvested.
The closing share price for Bio-Rad Laboratories, Inc. (BIO) stock was $297.17 for Wednesday, June 3, 2026, up +2.01% from the previous day.
BIO Price Chart
BIO Key Metrics
See All MetricsBIO Earnings Preview
Next Earnings Date
Jul 30, 2026
51 days away
EPS Estimate
1.75
Revenue Est.
$623.99M
Last Quarter Results
EPS
$1.89
vs Estimate
$1.99
Revenue
$592.10M
vs Estimate
$589.91M
BIO Analyst Ratings
Consensus Rating
Based on 5 analysts
Average Price Target
$297.00
-0.1% downside
Low
$275.00
Current
$297.17
High
$320.00
BIO Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | N/A | $2.38 | N/A | 1 |
| Q2 2027 | N/A | $2.40 | N/A | 1 |
| Q3 2027 | N/A | $2.55 | N/A | 1 |
| Q4 2027 | N/A | $2.74 | N/A | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $9.96 | N/A | 2 |
| FY 2028 | N/A | $11.15 | N/A | 1 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | N/A | $612.50M | N/A | 1 |
| Q2 2027 | N/A | $649.98M | N/A | 1 |
| Q3 2027 | N/A | $677.66M | N/A | 1 |
| Q4 2027 | N/A | $730.47M | N/A | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $2.66B | N/A | 2 |
| FY 2028 | N/A | $2.76B | N/A | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
BIO Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1BIO | $8.03B | $297.17 | +2.01% | +31.77% | -12.56% | +7.17% |
BIO Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz